nach oben

Erschienen in:

08.05.2023 | Typ-2-Diabetes | DDG Praxisempfehlungen

Adipositas und Diabetes

verfasst von: Prof. Dr. med. Jens Aberle, Anne Lautenbach, Svenja Meyhöfer, Sebastian M. Meyhöfer, Markus Menzen, Lars Selig, Matthias Blüher

Erschienen in: Die Diabetologie | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://www.deutsche-diabetes-gesellschaft.de/behandlung/leitlinien) befinden sich alle PDFs zum kostenlosen Download. …

Lindström J, Louheranta A, Mannelin M et al (2003) The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3‑year results on diet and physical activity. Diabetes Care 26:3230–3236CrossRefPubMed

Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed

Lean MEJ, Powrie JK, Anderson AS et al (1990) Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 7:228–233CrossRefPubMed

Williamson DF, Thompson TJ, Thun M et al (2000) Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23:1499–1504CrossRefPubMed

Wing RR, Bahnson JL, Bray GA et al (2010) Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the look AHEAD trial. Arch Intern Med 170:1566–1575PubMed

Eeg-Olofsson K, Cederholm J, Nilsson PM et al (2009) Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: An observational study in 13,087 patients. Diabetologia 52:65–73CrossRefPubMed

Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43:487–493CrossRefPubMed

Wang Z, Hoy WE (2004) Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr 58:888–893CrossRefPubMed

Pischon T, Boeing H, Hoffmann K et al (2008) General and abdominal adiposity and risk of death in Europe. N Engl J Med 359:2105–2120CrossRefPubMed

10.

Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with diabetes or prediabetes: A consensus report. Diabetes Care 42:731–754CrossRefPubMedPubMedCentral

11.

Reynolds AN, Akerman AP, Mann J (2020) Dietary fibre and whole grains in diabetes management: Systematic review and meta-analyses. PLoS Med 17:e1003053CrossRefPubMedPubMedCentral

12.

Landgraf R, Aberle J, Birkenfeld AL et al (2019) Therapy of type 2 diabetes. Exp Clin Endocrinol Diabetes 127:S73–S92CrossRefPubMed

13.

Lean ME, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 391:541–551CrossRefPubMed

14.

Gregg EW, Chen H, Wagenknecht LE et al (2012) Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 308:2489–2496CrossRefPubMedPubMedCentral

15.

Nationale VersorgungsLeitlinie (NVL) Typ– Diabetes. 1. Aufl.

16.

Kay SJ, Fiatarone Singh MA (2006) The influence of physical activity on abdominal fat: A systematic review of the literature. Obes Rev 7:183–200CrossRefPubMed

17.

Piercy KL, Troiano RP, Ballard RM et al (2018) The physical activity guidelines for Americans. JAMA 320:2020CrossRefPubMedPubMedCentral

18.

Vilsbøll T, Christensen M, Junker AE et al (2012) Effects of glucagon-like peptide‑1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ 344:d7771CrossRefPubMedPubMedCentral

19.

Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:11–22CrossRefPubMed

20.

Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989–1002CrossRefPubMed

21.

Rubino DM, Greenway FL, Khalid U et al (2022) Effect of weekly subcutaneous semaglutide vs daily Liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327:138–150CrossRefPubMedPubMedCentral

22.

Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348CrossRefPubMed

23.

Liu C, Li C, Cai X et al (2021) Discovery of a novel GLP-1/GIP dual receptor agonist CY‑5 as long-acting hypoglycemic, anti-obesity agent. Bioorg Chem 106:104492CrossRefPubMed

24.

Gautier JF, Choukem SP, Girard J (2008) Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 34:S65–S72CrossRefPubMed

25.

Alvarez E, Martínez MD, Roncero I et al (2005) The expression of GLP‑1 receptor mRNA and protein allows the effect of GLP‑1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92:798–806CrossRefPubMed

26.

Rosenstock J, Wysham C, Frías JP et al (2021) Efficacy and safety of a novel dual GIP and GLP‑1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398:143–155CrossRefPubMed

27.

Frías JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385:503–515CrossRefPubMed

28.

Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387:205–216CrossRefPubMed

29.

Rubino F, Nathan DM, Eckel RH et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care 39:861–877CrossRefPubMed

30.

S3-Leitlinie (2018) Chirurgie der Adipositas und metabolischer Erkrankungen. Version 2.3

31.

Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum DR, Belle SH, King WC et al (2009) Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 361:445–454CrossRef

32.

Birkmeyer NJO, Dimick JB, Share D et al (2010) Hospital complication rates with bariatric surgery in Michigan. JAMA 304:435–442CrossRefPubMed

33.

Aberle J, Reining F, Dannheim V et al (2012) Metformin after bariatric surgery—An acid problem. Exp Clin Endocrinol Diabetes 120:152–153CrossRefPubMed

Titel: Adipositas und Diabetes
verfasst von: Prof. Dr. med. Jens Aberle
Anne Lautenbach
Svenja Meyhöfer
Sebastian M. Meyhöfer
Markus Menzen
Lars Selig
Matthias Blüher
Publikationsdatum: 08.05.2023
Verlag: Springer Medizin
Schlagwörter: Typ-2-Diabetes
Adipositas
Bariatrische Chirurgie
Adipositas
Liraglutid
Metformin
Bariatrische Chirurgie
Semaglutid
Erschienen in: Die Diabetologie / Ausgabe 4/2023
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-023-01037-0

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

DDG Praxisempfehlungen: Diabetes, Sport und Bewegung

Mitteilungen des BDE

Sehvermögen bei schwerer Retinopathie nach 35 Jahren Diabetes mellitus Typ 1

CME: Depressionen bei Diabetes mellitus (Teil 1)

Mitteilungen des BDI

Welchen Sport sollten Diabetiker machen?

Praxisempfehlungen der Deutschen Diabetes Gesellschaft